MSD Polska maintains the status of a Research and Development Center

Companies with Research and Development Center (R&D) status in Poland invest hundreds of millions of zlotys annually in research and development, resulting in an increase in innovative projects and the establishment of new laboratories and design teams. These investments create specialized jobs for highly skilled professionals and scientists. Strong research centers drive added value in the economy, and Poland strengthens its position as a regional technology hub in Central and Eastern Europe.

MSD Polska's annual R&D expenditures exceed PLN 200 million. Over the past ten years, the company has allocated over PLN 1.2 billion to R&D.

According to the report "Commercial Clinical Trials in Poland", Poland's advantages in the clinical trials market include: higher productivity of centers, lower costs of initiating trials compared to established markets, higher productivity of centers and a good reputation for quality.

MSD Polska is one of only four companies representing the international biopharmaceutical sector among 59 companies that were selected based on detailed and rigorous criteria.

For years, the company has been investing heavily in the development of innovative therapies and clinical trials at centers around the world. In Poland, it currently conducts 165 clinical trials at over 500 centers, involving over 4,100 patients, 85% of which involve innovative oncology therapies , such as immunotherapy, individual neoantigen-based therapies (INT), and immunoconjugates (ADC). The remaining research focuses on issues related to cardiovascular diseases (5%), vaccine research (3%), antimicrobial therapy (3%), and autoimmune diseases (4%).

MSD Polska continually develops its collaborations with Polish universities and research institutes through partnerships, internship programs, and joint research. Such collaborations strengthen the R&D ecosystem, where academic discoveries are quickly translated into practical therapeutic solutions.

"Maintaining our R&D center status for the fifth consecutive year underscores our unwavering commitment to the development of innovation and clinical trials in Poland, while constantly focusing on patient needs. This distinction strengthens our presence in the domestic market and allows us to participate in groundbreaking projects and strategic collaborations. It demonstrates the real impact of our efforts and confirms that MSD Polska is a reliable and valued partner who prioritizes improving the quality of life for patients," says Justin Gandy , Managing Director of MSD Polska.

In May 2025, the company introduced an interactive clinical trial search engine in Polish, allowing users to filter projects by therapeutic area, study phase, and site location. This tool increases transparency and provides patients and physicians with quick and free access to the latest information.

"At MSD, we have many years of experience in developing new treatments, contributing to the development of modern medicine. By launching the search engine, MSD Polska is setting new standards in access to knowledge about research on new therapies for Polish patients, physicians, and the entire medical community. Our goal is to expand access to clinical trials and the participation of a broad range of patients, so that in the future our medicines and vaccines can serve the entire society," says Aneta Kwaśnik , Director of the Clinical Trials Department at MSD Polska.

For over 130 years, MSD Group companies, known as Merck in the United States and Canada, have provided medicines and vaccines for a wide range of serious diseases, pursuing a mission to save and improve the lives of patients worldwide. This commitment to patient health is demonstrated by expanding access to healthcare through programs and partnerships. Today, MSD Group companies continue to lead research into the prevention and treatment of diseases that threaten humans and animals, including cancer and infectious diseases. MSD aspires to be a leading biopharmaceutical company, conducting intensive research on a global scale.

MSD has been operating in Poland since 1991 with a mission to provide innovative healthcare solutions.

Copyrighted material - reprint rules are specified in the regulations .